Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European biotech financing gravitates to Benelux

This article was originally published in Scrip

Executive Summary

European entrepreneurs looking to establish new biotech companies are more likely to raise the funds they need by looking to the Benelux rather than the traditional powerhouses of the UK and Germany. Dr Edwin Moses, chief executive officer and chairman of Ablynx, the Ghent-based camelid antibody company and a serial entrepreneur, doubts whether start-ups can raise the hundreds of millions of Euros necessary to discover and develop new medicines in any market other than those emerging in the Benelux countries.

You may also be interested in...



Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

Stock Scan April 2018: Pharma's Fizz Falls Flat

In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel